Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis - 2How many ships have been attacked in the Gulf since start of Iran war?
- 3ISS astronaut snaps stunning nighttime photo of Florida and Cuba | Space photo of the day for Dec. 29, 2025
- 4Presenting Nintendo's New Pastel Satisfaction Con Tones for Switch Gamers: 3 Upscale Choices
- 5Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Don’t let food poisoning crash your Thanksgiving dinner
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- This Week In Space podcast: Episode 186 — Snow on the Moon?
- 'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Astronauts welcome arrival of new crewmates | On the International Space Station this week Nov. 24-28, 2025
- Heartfelt Objections to Visit with Your Adored One
- Russian strikes on Ukraine kill 5 people and wound 30 more
- Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
